Press Release - HBM Holdings

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release

Press Release In the News Image Library Awards & Recognitions

March 22, 2021

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 22, 2021 Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...
View more
March 12, 2021

Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial

Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 12, 2021 Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...
View more
February 26, 2021

Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors

Cambridge, MA, Rotterdam, NL, Suzhou, CN – February 26, 2021. Harbour BioMed (HBM) (HKEX:02142) today announced that the China National...
View more
January 28, 2021

Harbour BioMed’s Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 28, 2021. Harbour BioMed (HBM) (HKEX: 02142.HK) announced today that China Center for...
View more
December 17, 2020

Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange

CAMBRIDGE, Mass., SUZHOU, China, December 17, 2020 – HBM Holdings Limited (“Harbour BioMed”, “HBM” or the "Company”; S...
View more
December 15, 2020

Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, The Netherlands, December 14, 2020 – Harbour BioMed (HBM)(HKEX:02142) and Utrecht University (UU) today announc...
View more
December 09, 2020

HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering

This press release is NOT for release, publication, distribution, directly or indirectly, in or into the United States (including its terri...
View more
November 16, 2020

Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society

The proof-of-concept study demonstrated efficacy, safety, and tolerability of Tanfanercept for the treatment of moderate-to-severe dry eye disease (DED) in Chi...
View more
September 30, 2020

Harbour BioMed Announces Dosing of First Patient in Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia

Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 30, 2020. Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today ...
View more
September 21, 2020

Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

Cambridge, MA, Rotterdam, NL, Suzhou, CN – September 21, 2020. Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company ...
View more